Erratum to: J Headache Pain DOI 10.1007/s10194-008-0046-6
This article unfortunately contained errors in two places.
1. The two columns of data in Table 1 were under the wrong headings. The correct version of Table 1 is given here:
Table 1
Relative proportions of standardised medication units (SU) among different countries comparing weighted and unweighted proportions
Relative proportions of ASA consumption | Unweighted (%) | Weighted by mg ASA (%) |
|---|---|---|
USA | 58.2 | 48.3 |
Germany (West) | 16.0 | 19.7 |
Canada | 12.2 | 10.7 |
France | 9.7 | 16.7 |
Sweden | 1.1 | 1.3 |
Switzerland | 0.7 | 0.8 |
Austria | 1.7 | 1.8 |
Belgium | 0.3 | 0.6 |
Australia | 0.1 | 0.1 |
Total 9 countries | 100 | 100 |
Anzeige
2. Incorrect percentages were given in the last paragraph of the “Results” section, immediately before the “Discussion”. The corrected paragraph is as follows:
In 2005 in the prescription (Rx) group of N2B analgesics, combination products accounted for approx. 33% of all Rx analgesics in terms of SU. The most important combinations are tilidine plus naloxone (14% of all SU in the Rx group), followed by codeine plus paracetamol (12%). The predominating single products in the Rx group are metamizole (36%) and tramadol (21%). Growth in the Rx group can be seen for both the combinations named and the single products.
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (
https://creativecommons.org/licenses/by-nc/2.0
), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.